Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell ResponseMariëtte I.E. van Poelgeest, Sjoerd H. van der Burg, G. J. Fleuren et al.|Clinical Cancer Research|2016Cited by 166
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod TreatmentMariëtte I.E. van Poelgeest, Sjoerd H. van der Burg, Manon van Seters et al.|Clinical Cancer Research|2005Cited by 92
The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget DiseaseM. van der Linden, Joanne A. de Hullu, K.A.P. Meeuwis et al.|JMIR Research Protocols|2017Cited by 29
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanomaJoris L. Vos, Charlotte L. Zuur, Joleen J.H. Traets et al.|JCI Insight|2024Cited by 22
The immune cell infiltrate in the microenvironment of vulvar Paget diseaseM. van der Linden, Mariëtte I.E. van Poelgeest|Gynecologic Oncology|2018Cited by 17